Comparative Pharmacology
Head-to-head clinical analysis: BIORPHEN versus DILANTIN 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIORPHEN versus DILANTIN 125.
BIORPHEN vs DILANTIN-125
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
None Documented
None Documented
Terminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
Terminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Category C
Category C
Anticonvulsant
Anticonvulsant